Astrazeneca establishes a global R&D strategic center in Beijing

On the 25th, AstraZeneca officially launched its Global R&D Beijing Strategic Center, which is AstraZeneca's sixth global and second strategic R&D center in China, aimed at accelerating the translation of early drug research results into clinical development. AstraZeneca also announced collaborations with the University of Cambridge, the Beijing Municipal Science and Technology Commission, the Management Committee of Zhongguancun Science Park, and the Management Committee of Beijing Economic and Technological Development Area. AstraZeneca's UK Chairman, Pascal Soriot, stated that this collaboration will bring together experts and professional capabilities, establish a two-way connection between Beijing and the University of Cambridge, and achieve "in China, for China," as well as "in China, for the world," viewing China as a true internal source of innovation while also engaging in external cooperation in China